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Abstract
Chronic pain is a vexing worldwide problem that causes substantial disability and consumes
significant medical resources. Although there are numerous analgesic medications, these work
through a small set of molecular mechanisms. Even when these medications are used in combination,
substantial amounts of pain often remain. It is therefore highly desirable to develop treatments that
work through distinct mechanisms of action. While agonists of nicotinic acetylcholine receptors
(nAChRs) have been intensively studied, new data suggest a role for selective antagonists of nAChRs.
α-Conotoxins are small peptides used offensively by carnivorous marine snails known as Conus. A
subset of these peptides known as α-conotoxins RgIA and Vc1.1 produces both acute and long lasting
analgesia. In addition, these peptides appear to accelerate the recovery of function after nerve injury,
possibly through immune mediated mechanisms. Pharmacological analysis indicates that RgIA and
Vc1.1 are selective antagonists of α9α10 nAChRs. A recent study also reported that these α9α10
antagonists are also potent GABA-B agonists. In the current study, we were unable to detect RgIA
or Vc1.1 binding to or action on cloned GABA-B receptors expressed in HEK cells or Xenopus
oocytes. We review the background, findings and implications of use of compounds that act on α9*
nAChRs.
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Introduction
Chronic pain is estimated to affect millions of people world-wide and is one of the most
common reasons for physician visits [1]. Nociception is the neural processes of encoding and
processing noxious stimuli. Mechanical, chemical and thermal insults stimulate nerve endings
referred to as nociceptors. The stimulated nociceptors transmit signals, via the dorsal horn of
the spinal cord to the brainstem, midbrain and cerebral cortex. Descending pathways may
further modulate nociceptive activity [2]. Inflammation may cause direct painful stimuli as
well as sensitize nociceptors to stimulation [3]. Thus, there are multiple points along the pain
pathway that represent opportunities for therapeutic intervention. Despite this, there are only
a limited number of mechanisms through which current pain medications work. Major classes
of analgesics include opioids, non-steroidal anti-inflammatory drugs, antidepressants, and
anticonvulsants. Although these treatments provide relief, the effects are often incomplete and
complicated by serious side effects and/or tolerance. Thus, therapeutics with novel mechanisms
of actions are desperately needed [4].
Chronic pain is that which persists beyond the healing phase following an injury. Cytokines
and chemokines released from immune cells are thought to play a pivotal role not only in
inflammatory pain, but also in neuropathic pain following damage to neuronal tissue [3]. α-
Conotoxins RgIA and Vc1.1 have recently come to attention not only for their ability to produce
acute analgesia, but, of particular interest, for their ability to produce long lasting analgesia
and restoration of nerve function possibly through immune mediated mechanisms [5,6].
Overview of α9* nAChR pharmacology
Nicotinic acetylcholine receptors (nAChRs) are allosteric transmembrane proteins assembled
from one or more α subunits (α1-α10) either alone or together with one or more non-α subunits
(β1–β4) [7,8]. Individual subtypes of nAChRs have unique pharmacological and biophysical
properties as well as expression patterns that enable the possibility that subtype selective
compounds may have distinct therapeutic applications with a restricted set of side effects
[9-12]. nAChR subunits may be divided into 2 broad classes. Alpha subunits have a defining
“cysteine loop” that contains two vicinal cysteine residues, whereas non-alpha subunits lack
this cysteine loop. Alpha subunits may be further divided into two clades based on phylogenetic
analysis. In mammals, one clade consists of α7, α9 and α10 subunits [13,14]. α7, α9 and
α9α10 nAChRs are all potently blocked by α-bungarotoxin [15-17]. Both the α7 and the α9
subunit can assemble into a functional homopentamer [16]. In contrast the α10 subunit has
only been functionally co-expressed with an α9 subunit [17]. In Xenopus oocytes, the co-
injection of α9 and α10 subunits boosts functional nAChR expression 100-fold or more
compared to injection of α9 alone. [17,18]. α9α10 nAChRs have a number of notable
characteristics (see Table 1). While ACh activates these receptors, the classic nicotinic agonist
nicotine does not. Moreover, nicotine blocks ACh-evoked currents [16,17]. Thus, although
α9 and α10 are members of the nicotinic family based on gene homology, nicotine is an
antagonist of α9 and α9α10 nAChRs. Cytisine and epibatine, other well-characterized agonists
of other nAChR subtypes are also antagonists of α9 nAChRs [19]. In contrast the muscarinic
agonist oxotremorine is a partial agonist of α9 and α9α10 nAChRs [17]. The classic muscarinic
agonist, muscarine, as well as the classic antagonist atropine, block α9 and α9α10 nAChRs
[16,17]. Choline, often referred to as an α7-selective agonist is also a potent partial agonist of
α9 and α9α10 nAChRs [18]. α–bungarotoxin and methyllycaconitine are antagonists of α9*
nAChRs [17,18] [20]. In addition a number of non-cholinergic antagonists also potently block
α9α10 nAChRs; these include strychnine (glycine receptor antagonist), bicuculline (GABA-
A antagonist) and ICS - 205, 930 (5HT3 receptor antagonist) [17]. Thus, α9α10 nAChRs have
a pharmacological profile unknown for any other nicotinic or muscarinic cholinergic receptor
subtype.
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α–Conotoxins that block α9α10 nAChRs
α-Conotoxins are small disulfide rich peptides, 13 to 20 amino acids in length, which are found
in the venom of carnivorous marine snails known as Conus. The 500 to 700 different species
of cone snails comprise perhaps the richest natural sources of ligands targeted to nAChRs
[21]. Cone snails prey on organisms from five different phyla that utilize cholinergic
neurotransmission. Thus, there has been intense evolutionary pressure to develop peptides
targeted to different molecular forms of nAChRs. α–Conotoxins have historically been purified
from venom. More recently the ability to predict toxin sequences by PCR of α-conotoxin genes
has led to a substantial increase in the number of these ligands for characterization [21,22].
Three α-conotoxins have now been reported to be antagonists at α9α10 nAChRs. The first
recognized peptide was α-conotoxin PeIA from the venom of Conus pergrandis. α–Conotoxin
PeIA potently blocks α9α10 nAChRs but not α7 or α1* nAChRs [23]. In contrast, the snake
toxin α–bungarotoxin, blocks α9α10, α7 and α1 nAChRs. However, among non-α–
bungarotoxin-sensitive receptors, α-conotoxin PeIA is also active on α3β2 and α6β2β3
nAChRs. We therefore used a phylogenetic approach to identify other α-conotoxin sequences
that might be more selective. α-Conotoxin RgIA was isolated from Conus regius and found to
be both potent and selective for heterologously expressed as well as native α9α10 nAChRs
[24]. α-Conotoxin RgIA is the most selective α9α10 antagonist yet reported. One additional
peptide that blocks α9α10 nAChRs is α-conotoxin Vc1.1, also known as ACV1. α–conotoxin
Vc1.1 from Conus victoriae was originally identified by gene sequencing and identified as a
neuronal nAChR antagonist based on its ability to block nicotine and ACh-evoked
norepinephrine release from bovine adrenal chromaffin cells [25]. It was subsequently shown
to block heterologously expressed nAChRs in Xenopus oocytes with highest potency for
α9α10 nAChRs [5,26]. Vc1.1 also blocks α6* nAChRs with lower potency [5]. Each of the
three α-conotoxins, PeIA, RgIA and Vc1.1 has been synthesized by solid phase methods [23,
24,27]. The sequences of these peptides are shown in Table 2 and the specificities in table 3.
Three-dimensional structures of these peptides have been determined by nuclear magnetic
resonance [27-29] enabling receptor docking studies [30].
Acute antinociceptive effects of α9α10 nAChR antagonists
The subcutaneous or intramuscular administration of α9α10 selective antagonists acutely
alleviates pain resulting from traumatic, inflammatory, or metabolic neuronal injury. The
chronic constriction nerve injury model of neuropathic pain (CCI), which involves both a
traumatic (loose constriction of the sciatic nerve) and inflammatory (chromic gut suture)
component [31], has been utilized repeatedly to assess the efficacy of α9α10 nAChR
antagonists. This model of neuropathic pain results in painful response to a normally non-
painful stimulus (allodynia) and an exaggerated response to a painful stimulus (hyperalgesia)
within 7 days post-injury. Subcutaneous administration of Vc1.1 in doses of 24, 80, 160, 240,
or 800 μg/kg in rat dose-dependently reverse CCI-induced mechanical allodynia by
approximately 54-80%, with a peak analgesic effect of 1 hour; the highest concentrations have
an extended effect lasting up to 24 hours post-administration [5,32,33]. CCI-induced
mechanical hyperalgesia, measured by paw withdrawal to pressure, is also reduced dose-
dependently following the systemic administration of α9α10-selective antagonists.
Administration of Vc1.1 (0.036, 0.36, or 3.6 μg/200 μl) or RgIA (0.02 or 0.2 nmol/200 μl) into
the musculature overlying the constricted sciatic nerve alleviates mechanical hyperalgesia from
1 to 4 hours [6,34,35]. This analgesic response to intramuscular administrations of Vc1.1 (0.36
or 3.6 μg/200 μl) or RgIA (0.2 nmol/200 μl) is consistent across 7 days without the development
of tolerance [34], [6]. Similar administration of the N-type Ca++ channel blocker, ω-conotoxin
MVIIA (0.53 μg/200 μl), has no effect [35]. Others have reported efficacy with topical or local
application of MVIIA [36], [37]. The effect of Vc1.1 is not necessarily a localized, direct effect
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on the peripheral nerves in the hind leg because the administration of Vc1.1 (0.36 μg and 3.6
μg) in the contralateral hind leg is also capable of reversing mechanical hyperalgesia [34].
α9α10 nAChR antagonists show acute analgesic efficacy in an additional model of neuropathic
pain, the partial sciatic nerve ligation model (PSNL) [38]. In this model of traumatic nerve
injury, 1/3 to 1/2 of the sciatic nerve is ligated with silk suture to produce stable and long-
lasting mechanical allodynia and hyperalgesia. However, in the PSNL model, compared to the
loose ligation of the sciatic nerve in the CCI model, the injury to the nerve itself evokes the
immune response which contributes to axonal degeneration and the development of
neuropathic pain [39]. α-Conotoxin Vc1.1 (1 μg/kg, s.c.; 0.36 μg/200 μl, i.m.) significantly
reverses mechanical hyperalgesia in this model at 1 and 3 hours post-administration [34]. A
higher concentration of Vc1.1 (60 μg, i.m.) is also efficacious at reducing mechanical allodynia
over the same time course [26].
Vc1.1 is also an effective analgesic against pain resulting from a purely inflammatory insult.
Intraplantar adminstration of Complete Freund's Adjuvant (CFA) produces profound acute
mechanical hyperalgesia within 4 hours which is alleviated by subcutaneous administration of
Vc1.1 in concentrations ranging from 8 μg/kg – 2.4 mg/kg [33]. Peak analgesic effects of the
highest concentration of Vc1.1 (2.4 mg/kg) were observed at 1 and 1.5 hours and paw
withdrawal thresholds remained elevated 3 hours post-Vc1.1 administration [33].
In a rat model of diabetic neuropathy, pancreatic β-cells are destroyed following the injection
streptozotocin (STZ) resulting in pronounced hyperglycemia and glucosuria within 24 hours
and the development of mechanical allodynia and hyperalgesia within 5 - 7 days [40,41]. Vc1.1
(300 μg/kg, s.c.) administration significantly reduces mechanical allodynia in diabetic rats for
a prolonged period of at least 6 hours [33]. However, an acute analgesic effect on mechanical
hyperalgesia is not observed with this dose in this model [33].
Vc1.1 (known as ACV1) was tested in human clinical trials [42]. In a phase 1 safety study,
there was no evidence of systemic drug-related adverse effects from single or multiple doses
[43]. ACV1 progressed to phase 2A trials, but development was halted after in-vitro data
indicated that Vc1.1 was ∼100-fold less potent on human α9α10 vs. rat nAChRs [44]. Required
dosage adjustment for humans was judged to be cost-prohibitive [45].
Cumulative antinociceptive effects of α9α10 nAChR antagonists
As mentioned above, the analgesic effects of the higher concentrations of α9α10 nAChR
antagonists often exhibit efficacy as long as 24 hours post-administration [34] [6], a time point
at which serum levels of Vc1.1 are negligible [33]. This prolonged analgesic effect is
compounded by repeated, once daily administration of α9α10 nAChR antagonists and
manifests as a gradual reduction of injury-induced mechanical allodynia and hyperalgesia over
time. This reduction in injury-induced behavioral hypersensitivity is supported by biochemical,
physiological, and immunohistochemical studies that suggest α9α10 nAChR antagonists effect
the underlying pathology of these pain models [6,34,46].
Repeated, once daily administration of Vc1.1 (0.36 and 3.6 μg/200μl, i.m.) or RgIA (0.36 and
3.6 μg/200μl, i.m.) produces a significant decrease in mechanical hyperalgesia in CCI rats
across 5 – 7 days when paw withdrawal thresholds are measured 24 hours post-antagonist
administration [6] [35]. Similar intramuscular administration of the N-type Ca++ channel
blocker, MVIIA, has no effect on mechanical hyperalgesia in CCI rats [35]. Vc1.1 (0.36 μg/
200 μl, i.m.; 1 μg/kg, s.c.) and RgIA (0.36 μg/200 μl, s.c.) also exhibit cumulative analgesia
in the PSNL model of neuropathic pain [33,34], [M. Vincler, unpublished observations].
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In addition to the cumulative effects of repeated Vc1.1 or RgIA administration on mechanical
hypersensitivity, changes in the underlying disease pathology of nerve injury and repair are
observed. Intramuscular administration of 0.2 nmol RgIA once daily for 5 days significantly
decreases the number of lymphocytes and macrophages at the site of injury in CCI rats [6].
Repeated intramuscular administration of Vc1.1 (0.36 and 3.6 μg) either in the ispilateral or
contralateral hind limb of CCI rats, significantly accelerates the functional recovery of
peripheral nerves distal to the ligation [34] whereas the N-type Ca++ channel blocker, MVIIA,
was without effect [35].
The cumulative analgesic effects of Vc1.1 are most pronounced in the STZ diabetic neuropathic
pain model. Repeated once daily administration of Vc1.1 (300 μg/kg, s.c.) produces a
significant alleviation of tactile allodynia and mechanical hyperalgesia at the 24 hour post-
administration time point following the third administration of Vc1.1 [46]. A continuing and
increasing alleviation of mechanical allodynia is observed over a 4 week time course of
repeated Vc1.1 administration at both 30 and 300 μg/kg [46]. Concomitant with this reversal
of mechanical allodynia, a significant decrease in markers of oxidative stress is observed.
Levels of lipid hydroperoxide in the sciatic nerve and nitrotyrosine in systemic blood of diabetic
rats treated with Vc1.1. (300 μg/kg) for 4 weeks are significantly lower than in diabetic rats
treated with vehicle [46].
Extended antinociceptive effects of α9α10 nAChR antagonists
Further support for the disease modifying impact of α9α10 nAChR antagonists can be provided
by the extended analgesic effects of Vc1.1 and RgIA that are observed once the antagonists
are no longer administered. The cumulative analgesic effects of 7 days of once daily Vc1.1
(0.36 and 3.6 μg, i.m.) on mechanical hyperalgesia in CCI and PSNL rats are measurable one
week after the cessation of treatment [34,35]. A similar effect has been observed with repeated
RgIA administration (0.31 μg, s.c, see figure 1). A significant reduction of tactile allodynia
and mechanical hyperalgesia remains 7 – 10 days following the cessation of 5 days of once
daily Vc1.1 administration (300 μg/kg, s.c.) to STZ diabetic rats (Figure 2) [35,46]. The detailed
molecular mechanism of prolonged analgesia is unknown. The off-rate kinetics for both RgIA
and Vc1.1 are rapid (τ < 1 min, see [24] and (unpublished observations)) and thus would not
account for sustained effects.
α–Conotoxins and GABA-B receptors
Recently there was a report indicating that α–conotoxins Vc1.1 and RgIA inhibit N-type
Ca++ channels via activation of GABA-B receptors [47]. Blockade of Ca++ channel currents
was observed in rat dorsal root ganglion neurons. However Vc1.1 did not directly inhibit cloned
N-type Ca++ channels heterologously expressed in Xenopus oocytes suggesting an indirect
mechanism for antagonism. Subsequent analysis in dorsal root ganglion neurons showed that
block of Ca++ current was pertussis toxin sensitive. Blockade of N-type Ca++ channels was
also prevented by co-incubation with GABA-B antagonists. Based on these observations it was
proposed that RgIA and Vc 1.1 modulate N-type Ca++ channels by activating G-protein
coupled GABA-B receptors and that agonism of GABA-B receptors, rather than blockade of
α9α10 nAChRs is responsible for the α–conotoxin analgesic effects. An analog of Vc1.1 known
as vc1a blocks α9α10 nAChRs but is not analgesic lending support to this hypothesis [26,42].
However, vc1a does not stimulate GABA-B receptors [47], yet retains the ability of Vc1.1 to
accelerate functional recovery of the injured nerve [48].
Does GABA-B activation account for α-conotoxin analgesic activity?
Activation of GABA-B receptors by baclofen has been shown to be analgesic. In addition,
activation of GABA-B receptors modulates activity of ion channels including Ntype Ca++
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channels [49]. Block of N-type Ca++ channels is analgesic and is the basis of the antinociceptive
properties of another well known Conus derived compound, ω-conotoxin MVIIA, an FDA
approved drug known as Prialt [50,51]. Thus, activation of GABA-B receptors by RgIA or
Vc1.1 could be analgesic via modulation of N-type Ca++ channels.
GABA-B receptors are members of the G-protein coupled receptor (GPCR) family and are
heterodimers composed of B1 and B2 subunits. GABA-B1 is responsible for GABA
recognition and GABA-B2 couples to the G-protein. The composite receptor mediates slow
synaptic inhibition [52,53]. Thus, from both structural and functional standpoints, GABA-B
receptors and nAChRs are quite dissimilar. We are not aware of previous reports of a potent
nAChR antagonist also acting as a potent GABA-B receptor agonist. Thus, there is no other
literature to evaluate as to what analgesic effects might be expected from a pure α9α10
antagonist vs. a mixed α9α10 antagonist/GABA-B agonist.
In contrast, GABA-B agonists have been well-studied. Baclofen, a prototypical GABA-B
agonist has been evaluated for over 25 years as an antinociceptive agent. Some characteristics
of baclofen-mediated analgesia substantially differ from the analgesia shown by α–conotoxin
α9α10 antagonists. First, use of GABA-B agonists leads to tolerance to the antinociceptive
effects which limits its use in the clinic [54]. A common property of GPCRs is that following
agonist activation, the receptor internalizes or rapidly recycles. Likewise, the state of GABA-
B receptor activation affects GABA-B receptor turnover in recombinant cells and neurons
[55]. In dorsal root ganglion, activation of GABA-B by baclofen leads to clathrin-dependent
internalization and recycling to the plasma membrane [56] (but see [57]). By contrast, use of
Vc1.1 and RgIA have thus far not been associated with tolerance (see above).
Second, the primary analgesic effects of baclofen appear to be centrally mediated (see [52] for
review). GABA-B receptors are present in the cerebral cortex, thalamus and dorsal horn of the
spinal cord consistent with a largely central site of action (though GABA-B receptors also are
present in dorsal root ganglia). CNS effects of baclofen include sedation, asthenia and
confusion, side effects that have hindered clinical development of other GABA-B agonists
[54]. In contrast, α–conotoxins as charged peptides are unlikely to cross the blood-brain-barrier
in significant quantity. Thus, the mechanism of action of Vc1.1 and RgIA is almost certainly
peripheral. Indeed intrathecal administration of 0.2 nmol/10 μl α–conotoxin RgIA is not
analgesic in spinal nerve ligated rats (M. Vincler, unpublished data).
Lack of activity of α-conotoxins on cloned GABA-B receptors
We sought to further investigate the effects of α-conotoxins Vc1.1 and RgIA on GABA-B
receptors. We first examined the ability of the conotoxins to displace binding of the competitive
antagonist [3H]CGP-54626 to GABA-B(1b,2) receptors transiently expressed in HEK cells.
Surprisingly, as seen in Figure 3, Kis for both compounds were greater than 10 μM. This is in
contrast to the 1.7 nM IC50 GABA-B mediated block of Ntype Ca++ channels previously
reported in dorsal root ganglion [47]. α-Conotoxins Vc1.1 and RgIA were also previously
reported to block N-type Ca++ channels via activation of endogenous Xenopus oocytes GABA-
B receptors [47]. However, other investigators have failed to detect endogenous GABA-B
receptors in oocytes [58]. GABA-B receptors are well known to couple to G protein-activated
inwardly rectifying K+ (GIRK) channels providing a way to readily observe GABA-function
in oocytes [58]. In the report detailing that heterodimerization is required for the formation of
functional GABA-B receptors, White and co-workers failed to find GABA-B responses in
oocytes that were not injected with both GABA-B(1a) and GABA-B2 subunits, along with
GIRK channels. In contrast, large inward currents were seen in 21/21 oocytes injected with
both GABA-B(1a) and GABA-B2 along with GIRK [58]. Similar results have been reported
by other groups [59] [60] [61]. We also failed to detect inward currents in defolliculated oocytes
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injected with GIRK(1,4) in the absence of co-injection of GABA-B(1b) and GABA-B2
subunits in 10/10 oocytes (data not shown). We next tested α-Conotoxins Vc1.1 and RgIA for
their ability to activate heterologously expressed human GABA-B receptors in Xenopus
oocytes. As seen in Figure 4, both conotoxins failed to either activate or block GABA-B
receptors. Thus, we were unable to demonstrate functional activity of conotoxins on cloned
human GABA-B receptors expressed in oocytes. We were also unable to confirm conotoxin
activation of endogenous Xenopus oocyte GABA-B receptors (because we did not observe any
response to GABA-B in the absence of cloned human receptors but in the presence of GIRK
channels).
We are unsure how to reconcile the present findings with those of Callaghan et al. There are,
however, several differences between the experiments. Callagahan et al., reported agonist
effects of conotoxins Vc1.1 and RgIA on rat and Xenopus GABA-B receptors. Our binding
and functional experiments were carried out with human GABA-B clones. Callaghan et al.,
assessed GABA-B as a function of block of N-type Ca++ channels. We assessed GABA-B as
a function of its ability to activate GIRK channels. In the latter case, one might speculate that
the coupling mechanism could differ between GABA-B receptors and GIRK channels versus
GABA-B receptors and N-type Ca++ channels and that RgIA and Vc1.1 activate only GABA-
B receptors coupled to N-type Ca++ channels. Such specificity would be most interesting but
is, as far as we know, unprecedented. Experiments with co-expressed GABA-B receptors and
N-type Ca++ channels should resolve this possibility.
Expression pattern of α9 and α10 nAChR subunits
In oocytes, α9 and α10 nAChRs co-assemble to form a receptor. Mutagenesis studies of α9
and α10 subunits indicate that in oocytes, the stoichiometry of the major functional nAChR is
α9(2)α10(3) [62]. The molecular composition and subunit stoichiometry of native α9* nAChRs
remains to be determined.
The function of native α9 and α10 nAChR subunits is best known in the auditory system. These
subunits assemble to form the receptor that mediates synaptic transmission between efferent
olivocochlear cholinergic fibers which descend from the brainstem and hair cells of the cochlea
[16,17]. For an extended review of this receptor in cochlear hair cells see Elgoyhen et al. this
issue. The α9α10 nAChR of outer hair cells inhibits amplification of sound brought about by
the active mechanism of these cells [63]. For a short period of time, before the onset of hearing,
inner hair cells are also innervated by efferent fibers and the receptor mediating synaptic
transmission at this synapse is again the α9α10 nAChR [64-66]. Although, after the onset of
hearing, inner hair cells continue to express α9 but not α10, no ACh-mediated responses are
observed when assessed by electrophysiological techniques [16,17,66,67]. This result indicates
that, in spite of the fact that α9 can form homomeric receptors in vitro [16], α10 subunits are
required for functional receptors in inner hair cells. Moreover, although in α10 knockout mice
a small percentage of outer hair cells exhibit small ACh-mediated responses, most likely due
to the activation of α9 homomeric receptors, these remnant cholinergic responses are
insufficient to drive normal olivocochlear inhibition of cochlear mechanics [17]. Thus, taken
together these results indicate that in the cochlea both α9 and α10 are strictly required in order
to assemble into a functional nAChR. Although both α9 and α10 nAChR subunits have been
described in the vestibular end organs, the function of the efferent system and of this receptor
subtype in these organs is still obscure [16,68-72].
Both α9 and α10 nAChR subunits are expressed in skin [18,73-75]. The non-neuronal
cholinergic system of human epidermis includes the keratinocyte ACh axis composed of the
enzymes mediating ACh synthesis and degradation, and two classes of ACh receptors, the
nicotinic and muscarinic receptors, mediating biological effects of the cutaneous
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cytotransmitter ACh. Regulation of keratinocyte cell–cell and cell–matrix adhesion is one of
the important biological functions of cutaneous ACh [75,76]. A series of nAChR subunits (e.g.
α3, α5, α7, β1, β2 and β4) in addition to α9 and α10 are expressed in skin [75]. Inactivation of
α9 signaling by pharmacologic antagonism and RNA interference in keratinocyte cultures and
null mutation in knockout mice delayed wound reepithelialization in vitro and in vivo,
respectively, and diminished the extent of colony scattering and cell outgrowth from the
megacolony. α9-containing nAChRs seem critical for completion of the very early stages of
epithelialization. By activating α9-containing nAChRs, ACh can control the dynamics and
strength of cell–cell cohesion, disabling of a trailing uropod and disassembly and reassembly
of focal adhesions, thus facilitating crawling locomotion [77]. Moreover, α9 autoantibodies
are present in patients with pemphigus vulgaris, a potentially fatal autoimmune mucocutaneous
blistering disease [74], thus suggesting the participation of this nAChR subunit in disease.
Whether α9 receptors signal as homomers or as α9α10 heteromers in skin has not been
established.
Expression sites of α9 and α10 nAChR subunits further include the nasal epithelium and the
pars tuberalis of the pituitary gland [16,18], human and rat urothelium [78,79], human and rat
placenta [80-83], rat heart [84] and dorsal root ganglia [85-87]. Furthermore, α9 (α10 not
investigated) is expressed in retina [88], sperm [89] and olfactory bulb [90], whereas α10 is
expressed in arteries [91,92] and rat sympathetic ganglia [93]. An oral epithelial cell line
[94] and the NT2-N neuronal phenotype cell line [95] only express α9. At sites where α9 is
expressed in the absence of α10, the possibility exists that it signals via the assembly of
homomeric α9 nAChRs, as has been reported in Xenopus oocytes [16]. However, the functional
significance of α10 at sites in which α9 is not expressed is unknown, since it has been reported
that α10 does not form functional ACh-gated channels in pairwise combination with other
neuronal nAChR subunits and does not modify the known properties of α7 nAChRs when
expressed in Xenopus laevis oocytes [17,18]. We note that a recent study has shown that for
several nAChRs, the available antibodies are not suited for immunolocalization under
commonly used conditions, since staining is similar in wild-type and subunit specific knockout
mice [96]. Therefore, caution should be taken when drawing conclusions using α9 and/or α10
nAChR antibodies until their specificity is verified in, for example, their respective knockout
mice.
Finally, both α9 and α10 are expressed in a variety of immune cells [97-101]. The α9 and α10
subunits were identified in Jurkat, MT2 and CEM T-cell lines, purified populations of CD3+,
CD4+ and CD8+ T-cells, CD19+ and CD80+ B cells, monocytes, macrophages and in tonsil
by various techniques including RT-PCR, single cell RT-PCR, Northern and Western blot
analysis and immunohistochemistry [97-100]. The expression of these subunits in blood
indicates that caution should be taken when concluding expression of these subunits in non-
leukocytes based on PCR experiments. The presence of functional cholinergic receptors in
leukocytes is expected given that an “extra neuronal” cholinergic system appears operational
in these cells. Choline acetyltransferase, an enzyme used to synthesize ACh, has been detected
in a variety of immune cells and T-Cells have been shown to synthesize ACh [102,103].
Immune cell function and chronic pain
The cumulative analgesic and restorative effects of Vc1.1 and RgIA may be due to
immunological effects. RgIA and Vc1.1 administration in rats significantly reduces the number
of choline-acetyltransferase positive lymphocytes and macrophages in the neural and
perineural area of chronic constriction nerve sciatic nerve injury [5,6]. Immune cells release
inflammatory mediators which produce pain and hyperalgesia. In addition, immune and
inflammatory mechanisms are operative in nerve-injury (neuropathic) pain [104,105]. Rats
that lack mature T-cells (athymic nude) have reduced mechanical hypersenstivity after nerve
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injury [106]. Resident macrophages act as sentinels against invasion and inflammatory
macrophages are recruited to the site of inflammation after injury. Depletion of macrophages
reduces hyperalgesia and Wallerian degeneration after nerve injury [39]. Mast cells may also
play a role in neuropathic pain states [107]. Alpha9 and α10 subunits are present in a variety
of immune cells (see above) and block of the formed receptor may modulate the response of
these immune cells. For a detailed review of the role of immune cells in chronic pain, see
[105].
Conclusions
α–Conotoxins are nicotinic antagonists that show acute analgesic efficacy, and intriguingly
also show an ability to accelerate functional recovery from nerve injury. α-Conotoxins RgIA
and Vc1.1 are the only known compounds that selectively block α9α10 vs. other nAChR
subtypes. Thus, there is no prior literature on non-conotoxin compounds to compare with the
analgesic effects of RgIA and Vc1.1. In contrast, there is a large pre-existing literature on
GABA-B agonists and analgesia. Analgesic α9α10 antagonist α–conotoxins do not have a
thereapeutic or side effect profile that closely matches that of GABA-B agonists. It is
conceivable, though, that α–conotoxins act on an unknown allosteric site to activate GABA-
B receptors and this leads to an atypical in-vivo response. Thus far, we have been unable to
further study this possibility as experiments to date with cloned GABA-B receptors have not
demonstrated GABA-B activation by α-conotoxins Vc1.1 or RgIA. The resolution of the
analgesic mechanism of action of RgIA and Vc1.1 must await further studies, perhaps
involving novel small molecule α9α10 antagonists or receptor subunit knock-out mice. In the
mean time, α-conotoxins Vc1.1 and RgIA represent novel chemical entities with unique
pharmacological actions and analgesic effects that may serve as prototypes for development
of additional therapeutic agents.
Materials and Methods
Competition binding
Binding to GABA-B receptors was assessed by a radioligand competition binding assay using
HEK293T cells transiently transfected with 10 μg each of human GABA-B(1b) and GABA-
B2 (Origene, Rockville, MD, (NM_001470.1 and NM_005458.5). Reactions contained [3H]
CGP54626 (American Radiolabelled Chemicals Inc, St Louis, MO) (2 nM final), CGP54626
(Tocris, Ellisville, MO) or α-conotoxins at various concentrations (ranging from 10 pM to 10
μM), and membrane fractions in assay buffer (50 mM Tris, pH 7.4, 2.5 mM CaCl2). After a
1.5-hr incubation, reactions were harvested onto filtermats (Filtermate A, Perkin-Elmer,
Waltham, MA) using a Perkin-Elmer Filtermate harvester. Filters were dried using microwave
radiation (∼30 sec. per filter), then a scintillant sheet (Meltilex, Perkin-Elmer) was melted onto
each. Filtermats with dried scintillant were sealed in sample bags and counted on a Trilux
Microbeta counter. Remaining bound radioactivity (in cpm) was normalized, with [3H]
CGP54626 binding in the absence of competitor defined as 100% and [3H]CGP54626 binding
in the presence of 10 μM unlabeled CGP54626 defined as 0%. Data were analyzed by non-
linear regression using the “one-site competition” model built into Graphpad Prism 4.0. Ki
values were calculated from IC50 values using the Cheng-Prusoff approximation.
GABA-B receptors expressed in Xenopus oocytes
Human GABA-B(1b), GABAB2 cDNAs and rat G protein-coupled inwardly rectifying
potassium channels (GIRK) 1 and 4 were kindly provided by Dr. Andrew Green
(GlaxoSmithKline, Uxbridge, Middlesex, UK). Human GABAB(1b) was encapsulated in the
pcDNA3.1(-) (Invitrogen, Carlsbad, CA), GABAB2 and rat GIRK1 were encapsulated in the
pcDNA3 (Invitrogen), whereas the rat GIRK4 was encapsulated in pBluescript KS(-)
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(Stratagene, La Jolla, CA). Human GABAB(1b) and GABAB2 plasmids were linearized using
EcoRI. Rat GIRK1 and GIRK4 were linearized using XbaI. For GABAB and GIRK receptor
expression, human GABA-B(1b), GABAB2, rat GIRK1 and rat GIRK4 mRNA in the ratio of
1:2:1:1 was used. mRNAs were transcribed in vitro using T7 mMessage mMachineTM
transcription kit (Ambion Inc., Austin, TX, USA). α-Conotoxins were synthesized as
previously described [108].
The experiments were performed with Animal Ethics approvals from The University of
Sydney. Female Xenopus laevis was anesthetized with tricaine (850 mg/500 mL). Several
ovarian lobes were surgically removed by a small incision on the abdomen of the Xenopus
laevis. The lobes were cut into small pieces and were rinsed thoroughly with oocyte releasing
buffer 2 (OR2; 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES (hemi-Na)). The lobes
were digested with collagenase A (2 mg/mL in OR2; Boehringer Manheim, Germany) at room
temperature. The oocytes were further washed with OR2 and stored in Frog Ringer buffer or
ND96 wash solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES
(hemisodium salt) supplemented with 2.5 mM sodium pyruvate and 0.5 mM theopylline until
ready for injection. Stage V-VI oocytes were selected and microinjected with 2 ng mRNA.
After injection, the oocytes were maintained at 18°C in the presence of ND96 wash solution
augmented with 2.5 mM sodium pyruvate, 0.5 mM theopylline and gentamicin at 50 mg/mL.
Whole-cell currents were measured using a two-electrode voltage clamp with a Digidata 1200,
Geneclamp 500B amplifier together with a Powerlab/200 (AD Instruments, Sydney, Australia)
and Chart version 3.5 for PC as previously described [109]. The recording microelectrodes
were filled with 3 M KCl and had resistance between 0.2 and 1 MΩ. Three to five days post-
injection, oocytes held at -60 mV were used for recording. While recording, oocytes were
initially superfused with Frog Ringer (ND96) wash for 5 min before switching to 45 mM K+
buffer (45 mM NaCl, 45 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM HEPES
(hemisodium salt)) and cells perfused with this buffer until a stable base current was reached.
Vc1.1 (500 nM, 1 μM and 3 μM) or RgIA (0.5 μM) were evaluated in the absence and presence
of a submaximal dose of GABA (3 μM), respectively, until maximal current was reached, at
which time the oocyte was washed for 5 to 10 min to allow complete recovery of response to
GABA (3 μM).
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nAChRs  
nicotinic acetylcholine receptors
ACh  
acetylcholine
CCI  
chronic constriction injury
PSNL  
partial sciatic nerve ligation
STZ  
streptozotocin
GPCR  
G-protein coupled receptor
GIRK  
G protein-activated inwardly rectifying K+ channel
CGP54626  
[S-(R*,R*)]-[3-[[1-(3,4-Dichlorophenyl)ethyl]amino]-2-hydroxypropyl]
(cyclohexylmethyl) phosphinic acid
McIntosh et al. Page 16
Biochem Pharmacol. Author manuscript; available in PMC 2010 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Extended analgesic effect of a-conotoxins Vc1.1 and RgIA
A, CCI rats (n=6/group) treated intramuscularly with saline, 0.36 μg/200 μl Vc1.1, or 0.53
μg/200 μl MVIIA for 7 days. Mean percent changes in post-injury mechanical hyperalgesia
are shown across weeks. * p < 0.05. Data from [35]. B, CCI rats (n = 8) treated s.c. with 0.31
μg RgIA for 3 days. Mean paw withdrawal thresholds (PWT) in grams are shown prior to injury
(Pre-CCI), 7 days post-injury (Post-CCI), across RgIA treatment days (D1, D2, D3), and 14
days following cessation of treatment (D -4 to D -14). * p < 0.05.
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Figure 2. Vc1.1 produces acute and extended analgesic effects in a rat model of diabetic neuropathic
pain
Hyperglycemic rats were produced by treatment with streptozotocin [110]. Six weeks later,
rats were treated with s.c. Vc1.1, 300 μg/kg/day for five days. A, Relief from allodynia. Mean
paw withdrawal thresholds to von Frey filaments applied to the plantar surface of the hindpaw
at 1, 3, 6 and 24 hrs post injection are shown across treatment days and 3 and 10 days post
Vc1.1 treatment. Note the acute analgesic effect on each treatment day that is partially
maintained 24 hours post-treatment. Note that analgesia appears cumulative over the 5 days
of injection and that analgesia is partially maintained for 10 days following cessation of Vc1.1.
B, Relief from hyperalgesia. Hyperalgesia was assessed using an Ugo Basile analgesia meter
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applied to the dorsal surface of the hind paw. Responses were measured 12 hrs following each
injection. Two measurements were taken between the metatarsals 2 & 3 and metatarsals 4 &
5 and the data averaged. Note that analgesia over treatment days appears cumulative over the
5 days of injection and is partially maintained for 10 days after cessation of Vc1.1. *P< 0.05,
n=4. Data provided by Zeinab Khalil and Bruce Livett, Department of Biochemistry and
Molecular Biology, The University of Melbourne, Parkville, Victoria 3010, Australia.
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Figure 3. α-Conotoxins Vc1.1 and RgIA do not potently displace [3H]CGP54626 binding
HEK293T cells were transiently transfected with GABA-B(1b) and GABA-B(2) subunits. α-
Conotoxins Vc1.1 and RgIA (concentrations ranging from 10 pM to to 10 μM) were tested for
their ability to displace the binding of the competitive antagonist [3H]CGP54626 as described
in Material and Methods. The Ki for both α-conotoxins was greater than 10 μM. Experiments
with unlabeled CGP54626 were used to define total and non-specific binding. n=3-6 for each
data point. Error bars are S.E.M.
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Figure 4. α-Conotoxins Vc1.1 and RgIA have no effect on GABA-B nAChRs
(a) Oocytes expressing human GABAB(1b,2) receptors coupled to GIRK1/4 were clamped at
-60 mV as described in Materials and Methods. In the presence of GABA (3 μM; duration
indicated by open bar), Vc1.1 (0.5 μM; duration indicated by closed bar) had no effect as a
positive or negative modulator of GABA (3 μM). (b) Bar graph showing the effect of three
concentrations of Vc1.1 (0.5, 1.0 and 3.0 μM) and RgIA (0.5 μM) in the presence GABA (3
μM). There was no significant inhibitory or potentiating effect on the GABA response. Data
is the mean ±S.E.M (n=3-6 oocytes).
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Table 1
Antagonists and agonists of α9α10 nAChRs
Antagonists IC50 (nM)
Nicotine 3,900
Atropine 1000
Muscarine 41,000
Strychnine 20
Bicuculline 1000
ICS-205,930 20
d-tubocurarine 110
methylycaconitine 7.5a
α-bungarotoxin 14b
PeIA 6.9
Vc1.1 19
RgIA 5.2
Agonists EC50 (nM)
Acetylcholine 13,800
DMPP partial agonist
Oxotremorine partial agonist
Choline partial agonistb
epibatidine partial agonistb
Values are for rat α9α10 except where noted.
a
human
b
rat α9χα10χ where χ denotes a subunit chimera composed of the N-terminal ligand binding domain of the nicotinic subunit and the C-terminal domain
of the 5-hydroxytryptamine 3A subunit. Data are from [1-5].
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Table 2
Amino acid sequences of α-conotoxins that block α9α10 nAChRs
α-Conotoxin Sequence
RgIA GCCSDPRCRYRCR
Vc1.1 GCCSDPRCNYDHPEIC#
PeIA GCCSHPACSVNHPELC#
#
indicates amidated C-terminus
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Table 3
IC50s of α-conotoxins and α-bungarotoxin
nAChR subtype PeIA RgIA Vc1.1 α-BgTx
α9α10 6.9 5.2 19 14
α7 1,800 4,700 >30,000 0.5
α1β1δε 16,000
α1β1δγ >30,000 4.9
α2β2 >10,000 >10,000 >10,000
α2β4 >10,000 >10,000 >10,000
α3β2 23 >10,000 7,300
α3β4 480 >10,000 4,200
α4β2 11,600 >10,000 >30,000
α4β4 >10,000 >10,000 >30,000
α6/α3β2β3 <100 >10,000 140
α6/α3β4 >10,000 980
Values shown are IC50s in nM at mammalian nAChRs expressed in Xenopus oocytes and are from: [1-6]. α-BgTx, α-bungarotoxin.
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